PP
VKTX icon

Paladin Partners’s Viking Therapeutics VKTX Stock Holding History

Paladin Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.52K Hold
200
– – ﹤0.01% 135
2026
Q2 		$7.8K Hold
200
– – 0.01% 140
2026
Q1 		$6.51K Hold
200
– – ﹤0.01% 141
2025
Q4 		$7.04K Buy
+200
New +$7.09K 0.01% 138

Other funds holding VKTX

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return
BFS
Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Paladin Partners's VKTX Position: Q3 2026 in Review

Paladin Partners held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 200 shares worth $6.52K. The position accounts for ﹤0.01% of the portfolio, ranked #135.

Paladin Partners first reported a position in VKTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $7.8K in Q2 2026. 11 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Paladin Partners held 200 shares of Viking Therapeutics worth $6.52K as of Q3 2026.
  • Paladin Partners left its Viking Therapeutics share count unchanged in Q3 2026.
  • Viking Therapeutics made up ﹤0.01% of Paladin Partners's portfolio in Q3 2026, its #135 holding.
  • Paladin Partners first reported a position in Viking Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Paladin Partners's Viking Therapeutics position peaked at $7.8K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.